{"entity":{"id":"chain-of-identity-and-custody","kind":"term","name":"Cell-product chain of identity and custody","aka":["cell-therapy traceability","COI and COC","chain of identity","chain of custody"],"tldr":"Identity records connect cells and products to their source and intended recipient. Custody records show who held them and what happened during handoffs.","summary":"Traceability preserves relationships across source material, engineering construct, processing lots, containers, samples and intended recipients. Chain of identity and chain of custody answer different questions: what material and recipient are associated, and who had responsibility at each stage under which recorded conditions. A coded identifier makes a relationship recordable; it does not independently prove that the label, material and recipient agree.","asOf":"2026-11-09","links":[{"label":"FDA: CAR T-cell development guidance, January 2024","url":"https://www.fda.gov/media/156896/download"},{"label":"ICCBBA: Chain of Identity standard ST-028, version 1.1.0 (June 2025)","url":"https://iccbba.org/wp-content/uploads/2025/08/1a7593_0aa7a5f7202c4b43be4cc11bcd2048ef.pdf"},{"label":"ICCBBA: single-patient collection examples IG-050, version 1.0.0 (December 2023)","url":"https://iccbba.org/wp-content/uploads/2025/08/1a7593_badfaf3c48d443f78006340096a671e0.pdf"}],"tags":[],"related":["apheresis","cell-therapy-orchestration-software","cell-therapy-cold-chain","car-t-manufacturing-process","allogeneic-cell-therapy"],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A collection can branch into processing lots, doses or test samples. Retain parent links and construct versions so a sample result can be attributed to the material it represents. One bag need not mean one manufacturing run or one dose; an allogeneic workflow can relate donor material to later recipients according to its actual design.","ICCBBA ST-028 version 1.1.0, June 2025, describes chain-of-identity relationships and responsibilities. IG-050 version 1.0.0, December 2023, gives bounded examples in which material is returned to the same patient; it explicitly does not cover one collection manufactured into therapies for multiple patients. That example scope must not be generalised into a complete donor-bank scheme.","In a fictional single-recipient example, collection A produces lot A, which branches into doses A1 and A2 and test sample S. Each child retains the parent link. A separate custody trail records handlers, handoff times and conditions. Keeping those links does not establish acceptable quality or clinical suitability.","Barcodes, biological identity assays, HLA typing, potency results and temperature traces are different evidence. None alone replaces the complete material/intended-recipient verification. A discrepancy or excursion requires investigation and the authorised quality disposition; an audit trail is evidence to assess, not a guarantee of safety.","FDA's CAR T-cell guidance addresses documented tracking from collection to administration and independent recipient/label checks. The required process is not equivalent to purchasing a particular orchestration system. Research samples, fresh products, cryopreserved products and in vivo carriers retain their own applicable identities and handling context."],"category":"Methods and models"},"route":"/terms/chain-of-identity-and-custody/","neighbours":{"term":[{"id":"apheresis","kind":"term","name":"Apheresis (leukapheresis)","route":"/terms/apheresis/"},{"id":"cell-manufacturing-outcomes","kind":"term","name":"Cell-manufacturing outcomes and nonconforming products","route":"/terms/cell-manufacturing-outcomes/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/"},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}]}}